Home > Boards > US OTC > Biotechs > Inhibitor Therapeutics Inc. (INTI)

On April 11, 2016 and April 14, 2016,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
smoke Member Profile
Member Level 
Followed By 26
Posts 1,876
Boards Moderated 0
Alias Born 05/06/01
160x600 placeholder
smoke Member Level  Tuesday, 04/19/16 08:29:54 AM
Re: db7 post# 330
Post # of 388 
On April 11, 2016 and April 14, 2016, HedgePath Pharmaceuticals, Inc. (the "Company") conducted initial closings (the "Initial Closings") of a private placement offering to accredited investors (the "Offering") of the Company's units (the "Units") at a price of $0.10 per Unit, with each Unit consisting of:
(i) one (1) share of the Company's common stock, par value $0.0001 per share (the "Common Stock"), and (ii) a five-year warrant to purchase one (1) share of Common Stock at an exercise price of $0.12 per share (the "Warrants"). The Company may sell up to 55,000,000 Units in the Offering, for aggregate gross proceeds of up to $5,500,000 (the "Maximum Amount"). No actual Units will be issued, and each investor will receive shares of Common Stock and Warrants only should they participate in the Offering. The Offering will terminate on April 29, 2016, but may be extended for an additional 30 days in the sole and absolute discretion of the Company. The Offering is being conducted on a "best efforts/no minimum" basis, meaning that the Company shall have the discretion to raise any amount in the Offering up to (but also less than) the Maximum Amount.

"Thoughts become deeds, choose the good ones"
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist